Tempus Acquires Personalis for $1.5 Billion
Tempus AI agreed to acquire Personalis for $16.25 per share, representing an enterprise value of approximately $1.5 billion net of Tempus’ existing ownership. The deal integrates Personalis’ tumor-informed minimal residual disease testing with Tempus’…
